Q. Where is BioCryst located?
Durham, North Carolina
BioCryst’s US headquarters is located in Durham, North Carolina, our European headquarters in Dublin, Ireland and our Discovery Center of Excellence in Birmingham, Alabama.
Q. What does BioCryst pharmaceuticals do?
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst’s antiviral drug peramivir (Rapivab) was approved by FDA in December 2014.
Q. How many employees does BioCryst have?
Founded in 1986, BioCryst has more than 50 employees and is experiencing continued growth. The Company’s headquarters are located in Research Triangle Park, North Carolina and its Discovery Center of Excellence is in Birmingham, Alabama.
Q. Who owns BioCryst Pharmaceuticals?
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission….New and Sold Out Positions.
| OWNER NAME | VANGUARD GROUP INC |
|---|---|
| SHARES HELD | 9,304,543 |
| CHANGE (SHARES) | -395,524 |
| CHANGE (%) | -4.078% |
| VALUE (IN 1,000S) | $115,376 |
Q. Is Bcrx a buy?
BioCryst Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.
Q. When did BioCryst go public?
March 1994
When was BioCryst founded and when did the company go public? BioCryst was founded in 1986 and completed its Initial Public Offering in March 1994. The Company’s stock is traded on the NASDAQ exchange under the symbol BCRX.
Q. Is BioCryst Pharmaceuticals a good buy?
Q. Will BioCryst go up?
Will Biocryst Pharmaceuticals stock price grow / rise / go up? Yes. The BCRX stock price can go up from 12.420 USD to 15.874 USD in one year.
Q. How many shares of BCRX are there?
Share Statistics
| Avg Vol (3 month) 3 | 2.75M |
|---|---|
| Shares Outstanding 5 | 179.79M |
| Implied Shares Outstanding 6 | N/A |
| Float 8 | 165.6M |
| % Held by Insiders 1 | 0.90% |
Q. Is BCRX overvalued?
High growth potential and slightly overvalued.
Q. Is BXRX a buy?
Out of 1 analysts, 1 (100%) are recommending BXRX as a Strong Buy, 0 (0%) are recommending BXRX as a Buy, 0 (0%) are recommending BXRX as a Hold, 0 (0%) are recommending BXRX as a Sell, and 0 (0%) are recommending BXRX as a Strong Sell. What is BXRX’s earnings growth forecast for 2021-2023?
Q. Why is BioCryst stock falling?
Shares of BioCryst (NASDAQ:BCRX), a biopharmaceutical company, are falling after the company reported third-quarter earnings results. A drop in top-line revenue and softer-than-expected guidance aren’t sitting well with investors, who have driven the stock 16.5% lower as of 11:50 a.m. on Wednesday.
